Home » Stocks » SCYX

SCYNEXIS, Inc. (SCYX)

Stock Price: $7.23 USD -0.27 (-3.60%)
Updated Jun 21, 2021 12:43 PM EDT - Market open
Market Cap 154.73M
Revenue (ttm) 12.05M
Net Income (ttm) -52.86M
Shares Out 25.80M
EPS (ttm) -3.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $7.23
Previous Close $7.50
Change ($) -0.27
Change (%) -3.60%
Day's Open 7.50
Day's Range 7.07 - 7.50
Day's Volume 270,192
52-Week Range 4.20 - 10.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 week ago - GlobeNewsWire

JERSEY CITY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

1 week ago - GlobeNewsWire

The FDA has approved Scynexis Inc's (NASDAQ: SCYX) Brexafemme (ibrexafungerp tablets) for oral use in patients with vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. Brexafemme re...

2 weeks ago - Benzinga

JERSEY CITY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

2 weeks ago - GlobeNewsWire

JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

1 month ago - GlobeNewsWire

Scynexis Inc (NASDAQ: SCYX) is taking out a loan to ensure it can hit the ground running for a potential commercial launch of ibrexafungerp for vaginal yeast infections as the PDUFA date of June 1 is ju...

1 month ago - Benzinga

JERSEY CITY, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

1 month ago - GlobeNewsWire

JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

1 month ago - GlobeNewsWire

JERSEY CITY, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

1 month ago - GlobeNewsWire

JERSEY CITY, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

2 months ago - GlobeNewsWire

JERSEY CITY, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

3 months ago - GlobeNewsWire

JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

3 months ago - GlobeNewsWire

JERSEY CITY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

3 months ago - GlobeNewsWire

JERSEY CITY, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

4 months ago - GlobeNewsWire

JERSEY CITY, N.J. & SHANGHAI--(BUSINESS WIRE)--SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infect...

4 months ago - Business Wire

JERSEY CITY, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warran...

5 months ago - GlobeNewsWire

JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The s...

6 months ago - GlobeNewsWire

JERSEY CITY, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purc...

6 months ago - GlobeNewsWire

JERSEY CITY, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

6 months ago - GlobeNewsWire

JERSEY CITY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

6 months ago - GlobeNewsWire

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel Ban NOW )....

6 months ago - Insider Monkey

JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

6 months ago - GlobeNewsWire

JERSEY CITY, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to potentially overcome and prevent difficult-to-treat and dru...

7 months ago - GlobeNewsWire

Three posters highlight the potential for ibrexafungerp use in treating and preventing serious fungal infections Three posters highlight the potential for ibrexafungerp use in treating and preventing se...

8 months ago - GlobeNewsWire

JERSEY CITY, N.J., Oct. 14, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...

8 months ago - GlobeNewsWire

Presentations to showcase in vitro activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida spp. and clinical data from VANISH-303 PHASE 3 trial evaluating ibrexafungerp as a tre...

8 months ago - GlobeNewsWire

JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista...

9 months ago - GlobeNewsWire

JERSEY CITY, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist...

10 months ago - GlobeNewsWire

In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal ye...

10 months ago - GlobeNewsWire

JERSEY CITY, N.J., July 29, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resist...

10 months ago - GlobeNewsWire

Clinical and preclinical studies demonstrate ibrexafungerp’s broad-spectrum activity and potential to treat a range of serious and life-threatening fungal infections Clinical and preclinical studies dem...

10 months ago - GlobeNewsWire

Discussion will be conducted via Webcast Call on Tuesday, July 14th at 10am Eastern Time

11 months ago - GlobeNewsWire

JERSEY CITY, N.J., June 08, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...

1 year ago - GlobeNewsWire

JERSEY CITY, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan...

1 year ago - GlobeNewsWire

JERSEY CITY, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant...

1 year ago - GlobeNewsWire

JERSEY CITY, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

1 year ago - GlobeNewsWire

JERSEY CITY, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resis...

1 year ago - GlobeNewsWire

SCYNEXIS has the ability, at its discretion, to efficiently access up to $20 million of capital

1 year ago - GlobeNewsWire

JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista...

1 year ago - GlobeNewsWire

Scynexis: A Promising Infectious Diseases Player For 2020

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in SCYNEXIS.

1 year ago - Zacks Investment Research

Scynexis (SCYX) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Investors need to pay close attention to SCYNEXIS (SCYX) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Scynexis (SCYX) delivered earnings and revenue surprises of 11.11% and -5.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

I expect LPAD designation to be granted to both FURI and CARES trials before the end of this year.

1 year ago - Seeking Alpha

Shares have risen by 25% since my January update piece.

1 year ago - Seeking Alpha

Scynexis is a development stage biotechnology developing a novel antifungal, Ibrexafungerp, with a high probability of success.

2 years ago - Seeking Alpha

Scynexis (SCYX) delivered earnings and revenue surprises of -20.00% and -24.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

About SCYX

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations wit... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 2, 2014
Stock Exchange
NASDAQ
Ticker Symbol
SCYX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SCYNEXIS stock is "Strong Buy." The 12-month stock price forecast is 25.44, which is an increase of 251.87% from the latest price.

Price Target
$25.44
(251.87% upside)
Analyst Consensus: Strong Buy